Pan-cancer landscape of homologous recombination deficiency [PDF]
Nature Communications, 2020 Cancers deficient in homologous recombination can benefit from treatment with poly ADP-ribose polymerase (PARP) inhibitors. Here, the authors generated a classifier that can predict homologous recombination deficiency from genomic data and suggest ...
Luan Nguyen +3 more
doaj +5 more sources
Targeting homologous recombination deficiency in uterine leiomyosarcoma
Journal of Experimental & Clinical Cancer Research, 2023 Background Uterine leiomyosarcoma (uLMS) is a rare and aggressive gynaecological malignancy, with individuals with advanced uLMS having a five-year survival of 0.2) but only two samples had a CHORD score > 50%, one of which had a homozygous pathogenic ...
Genevieve Dall +39 more
doaj +4 more sources
Leveraging homologous recombination repair deficiency in sarcoma
EMBO Molecular Medicine, 2023 Personalised oncology is at the forefront of cancer research. The goal of personalised oncology is to selectively kill cancer cells while minimising side effects on normal tissue.
Dea Slade, Joanna I Loizou
doaj +3 more sources
Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management
Clinics, 2018 Ovarian cancer patients with homologous recombination deficiencies exhibit specific clinical behaviors, and improved responses to treatments, such as platinum-based chemotherapy and poly (ADP-ribose) polymerase (PARP) inhibitors, have been observed ...
Renata Rodrigues da Cunha Colombo Bonadio +3 more
doaj +3 more sources
Assessing the association between homologous recombination deficiency scores and treatment response in localized and metastatic prostate cancer [PDF]
The Journal of Pathology: Clinical ResearchThe aim of this study was to evaluate the predictive value of homologous recombination deficiency scores for therapeutic efficacy in prostate cancer across various disease stages under different regimens.
Qiyu Zhu +11 more
doaj +2 more sources
Homologous Recombination Deficiency Scar: Mutations and Beyond—Implications for Precision Oncology [PDF]
Cancers, 2022 Homologous recombination deficiency (HRD) is a prevalent in approximately 17% of tumors and is associated with enhanced sensitivity to anticancer therapies inducing double-strand DNA breaks. Accurate detection of HRD would therefore allow improved patient selection and outcome of conventional and targeted anticancer therapies. However, current clinical
Jan Theys +2 more
exaly +3 more sources
Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity [PDF]
Cancers, 2021 Homologous recombination repair deficiency (HRD) can be observed in virtually all cancer types. Although HRD sensitizes tumors to DNA-damaging chemotherapy and poly(ADP-ribose) polymerase (PARP) inhibitors, all patients ultimately develop resistance to these therapies.
Sandra Van Wilpe +2 more
exaly +4 more sources
The Utility of NGS Analysis in Homologous Recombination Deficiency Tracking
Diagnostics, 2023 Several tumor types have been efficiently treated with PARP inhibitors (PARPis), which are now approved for the treatment of ovarian, breast, prostate, and pancreatic cancers.
Aikaterini Tsantikidi +21 more
doaj +4 more sources
Homologous recombination deficiency in primary ER-positive and HER2-negative breast cancer [PDF]
Communications MedicineBackground Homologous recombination deficiency (HRD) originating from inactivation of genes like BRCA1/BRCA2 is a targetable abnormality common in triple-negative breast cancer (TNBC).
Helen R. Davies +18 more
doaj +2 more sources
Constitutional BRCA1 Methylation is associated with high level of tumoral BRCA1 methylation and homologous recombination deficiency in triple-negative breast cancer [PDF]
npj Breast CancerTumoral BRCA1 promoter methylation occurs frequently in triple-negative breast cancer (TNBC) and contributes to homologous recombination deficiency (HRD).
Justine Pasanisi +21 more
doaj +2 more sources